Groundbreaking Graphene Neurotechnology Developed by ICN2 and Partners Set to Revolutionize Neuroscience and Therapeutic Applications
A groundbreaking study published in Nature Nanotechnology introduces an innovative graphene-based neurotechnology developed by the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and its collaborators. This cutting-edge technology, known as EGNITE (Engineered Graphene for Neural Interfaces), has the potential to bring about transformative advancements in neuroscience and medical applications.
The development of EGNITE, a flexible, high-resolution, high-precision graphene-based implantable neurotechnology, marks a significant milestone in the field of neuroelectronics and brain-computer interfaces. Through years of research under the European Graphene Flagship project, ICN2 and the University of Manchester have successfully created a novel class of graphene microelectrodes that exhibit low impedance and high charge injection, essential for efficient neural interfaces.
Preclinical studies conducted in collaboration with various neuroscience and biomedical experts have demonstrated the remarkable capabilities of EGNITE in recording high-fidelity neural signals with exceptional clarity and precision, as well as providing highly targeted nerve modulation. This unique combination of signal recording and nerve stimulation represents a major advancement in neuroelectronic therapeutics.
The international collaboration behind this groundbreaking technology, led by ICN2 researchers Damià Viana, Steven T. Walston, and Eduard Masvidal-Codina, has brought together experts from institutions such as the University of Barcelona, the National Graphene Institute in Manchester, and the Grenoble Institut des Neurosciences in France. The technology has been integrated into standard semiconductor fabrication processes at the Micro and Nanofabrication cleanroom of the IMB-CNM (CSIC).
The EGNITE technology has been patented and licensed to the spin-off company INBRAIN Neuroelectronics, based in Barcelona, which is spearheading the translation of this innovative graphene technology into clinical applications. CEO Carolina Aguilar is leading the charge towards the first-in-human clinical trials of EGNITE, with the support of IMB-CNM (CSIC) and other partners.
The potential of EGNITE to revolutionize neurotechnology and therapeutic applications is underscored by the ongoing efforts of ICN2 and its partners to advance and mature this technology. With plans to upscale production using established semiconductor fabrication processes, the future looks bright for the integration of graphene into cutting-edge neurotechnological materials.
The Nature Nanotechnology article detailing the development of EGNITE serves as a testament to the collaborative efforts and scientific leadership driving this transformative innovation. As the field of neurotechnology continues to evolve, the promise of graphene-based neurotechnology holds the key to unlocking new possibilities in neuroscience and medical applications.